Immunotoxin for treatment of metastatic colorectal cancer

Scientists at Oslo University Hospital have developed an immunotoxin, MOC31PE, which consists of a targeting function recognizing a surface marker present at increased levels in many cancer forms, coupled to a toxin component which kills the cancer cells. Several successful phase 1 clinical trials with MOC31PE have been completed, demonstrating good safety profile and promising efficacy data (increased survival) for patients with metastatic colorectal cancer, which today have very poor treatment options. Our data indicate that MOC31PE works through an immune-stimulatory mechanism which suggests combination with checkpoint inhibitors as a particularly attractive use. The current verification project thus aims to conclude a licensing agreement with a major pharma company with an existing checkpoint inhibitor on the market or in advanced clinical development. For these companies, MOC31PE would represent an opportunity to expand of the application of their checkpoint inhibitors to patient groups where they are not effective as single therapy, including metastatic colorectal cancer patients. In order to achieve the overall aim, the verification project aims to demonstrate superior effect of combining MOC31PE with checkpoint inhibitors in animal models of cancer with engrafted human immune system, as well as secure patent protection for the combination therapy. This will support negotiations with relevant pharma companies, towards securing a license agreement by the end of the project period.